Navigation Links
Old stain in a new combination
Date:5/20/2009

etocytes and thus improve the control of malaria," states Professor Dr. Olaf Mller, Project Head in the Department of Tropical Medicine and Public Health of the Hygiene Institute at the University of Heidelberg.

Methylene blue prevents transmission to mosquitoes

The appropriate component for such an alternative is a proven agent the methylene blue stain which has been given to malaria patients since the end of the 19th century has proven to be safe, well tolerated, and effective in combination with various malaria medications.

In the current study in Burkina Faso with 160 malaria patients between the ages of six and ten the Heidelberg scientists tested the effect of combination therapies with artemisinins and methylene blue on gametocytes in the blood. One group of the children received the standard treatment, consisting of a combination of artesunate and amodiaquine. Two other groups received methylene blue combined with one of the two drugs respectively. The physicians checked the number of gametocytes in blood samples three, seven, and fourteen days after the start of therapy.

Combination therapy is twice as effective as standard therapy

It was shown that both combination therapies are twice as effective against gametocytes as the standard therapy these parasites had almost completely disappeared in the first few days. "Methylene blue not only inhibits the formation of the reproductive forms, but also destroys already existing cells," explains Professor Mller. "In this way, the profiles of methylene blue and artemisinins, which quickly and effectively eliminate the parasites in the red blood cells, complement each other." Since the study group from Heidelberg has used methylene blue in Western Africa for years, it has already been adequately clinically tested severe or frequent side effects did not occur. Especially important is that the combination makes it more difficult for resistance to artemisi
'/>"/>

Contact: Prof. Olaf Mueller
Olaf.mueller@urz.uni-heidelberg.de
49-062-215-65035
University Hospital Heidelberg
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Grasslands: The future of sustainable agriculture
2. Going bananas for sustainable research -- scientists create fuel from African crop waste
3. K-State biologist collaborating with researchers in Africa on grassland sustainability, biodiversity
4. Organizational Change Management for Sustainability: The Harvard Case Study
5. Biofuels can provide viable, sustainable solution to reducing petroleum dependence
6. Symposium at UH will address how to put sustainability into practice
7. Biggest ever public investment in bioenergy to help provide clean, green and sustainable fuels
8. TXOTX, coordinated international project to contribute to sustainability of the marine resources
9. Abundance of ladybugs in olive orchards is an indicator of health and sustainability
10. Next generation microscopy: No stain, big gain
11. New publishing partnership for Energy for Sustainable Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... the only ones making exciting scientific discoveries these days. ... of scientists who are reporting the first glimpse of ... helps activate certain antibiotics and anti-cancer agents so that ... ACS, weekly journal Biochemistry . The student co-authors ...
... College Park, MD (July 27, 2010) -- Kites have a ... and his study of electricity -- including being used to ... sensors, because they were exposed to direct sunlight, were prone ... the University of Reading in the United Kingdom have developed ...
... MN Current research suggests that taking morphine can ... related report by Koodie et al, "Morphine suppresses tumor ... 2010 issue of the American Journal of Pathology ... analgesics used to relieve severe pain and suffering. ...
Cached Biology News:
(Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:2/27/2015)... DIEGO , Feb. 27, 2015  Pfenex Inc. ... the development of biosimilar therapeutics, today announced that it ... Francisco Marriott Marquis on March 2 nd at ... participate on a panel discussing the current state of ... of Biosimilars . For more information ...
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Calif., Feb. 27 Telik, Inc.,(Nasdaq: TELK ) ... per share,for the fourth quarter ended December 31, 2007, ... per share, for the comparable period in 2006., ... costs and,expenses were $13.5 million, compared with $19.5 million ...
... ZARS Pharma, Inc. announced,today that Rapydan(R) ... now received marketing authorization in Sweden, the ... Czech Republic, Greece, Ireland,Norway and Portugal following ... ZARS Pharma has licensed the European sales ...
... Fla., Feb. 27 Imaging,Diagnostic Systems, Inc., ... laser,optical breast imaging systems, will exhibit CT ... National Interdisciplinary Breast Cancer,Conference, March 1-5, in ... at booth,#43., (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ...
Cached Biology Technology:Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance 2Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance 3Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance 4ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 2ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 3CT Laser Mammography Technology to be Featured at Interdisciplinary Breast Cancer Conference 2
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
... The mycobacteria in ... cells to the injection site which enhances ... Freund's Adjuvant is used for the initial ... the subsequent boosts. Antigens (preferably in saline) ...
Biology Products: